Clinical trials of Revelumid tablets approved
November 14, 2025
Source: drugdu
74
Hengrui MedicineOn November 3, (600276) announced that it had received a drug clinical trial approval notice from the National Medical Products Administration (NMPA) for Revelumid tablets, agreeing to conduct a Phase III clinical trial for prostate cancer. The company's Revelumid tablets were approved for marketing in 2022 for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with a high tumor burden.
https://finance.eastmoney.com/a/202511133563619583.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
